Terumo Cardiovascular Systems Corporation
$22.7K 185 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Nippon Shinyaku Co.,Ltd
Nippon Shinyaku Co.,Ltd reported $22,687.78 across General Payments, Research, and Ownership to 18 physicians and teaching hospitals across 18 transactions.
- $22.7K
- All-tracks total
- 18
- Transactions
- 18
- Recipients
- +$21.8K
- General Payments vs PY2023
Nippon Shinyaku Co.,Ltd reported $22,687.78 across all CMS Open Payments tracks (General + Research + Ownership) to 18 physicians and teaching hospitals in Program Year 2024 - ranking #1517 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $22,687.78, averaging $1.3K per recipient.
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer nippon-shinyaku-co-ltd Nippon Shinyaku Co.,Ltd
$22.7K · #1517/1,925 · 0.0% industry · PY2024
- TOT $22.7K
- RANK #1517
- SHARE 0.0%
- TXN 18
- RCP 18
- CAT 4
- GEN $22.7K
- ΔGEN +$21.8K
- TOP1 94.7%
- PY 2024
Volume peers
Nearest volume peer: Terumo Cardiovascular Systems Corporation ($22.7K)
Nippon Shinyaku Co.,Ltd sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Nippon Shinyaku Co.,Ltd's CMS-reported General Payments increased by $21.8K (+2427.2%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: NIPPON SHINYAKU CO.,LTDPY2023: NIPPON SHINYAKU CO.,LTDPY2024: Nippon Shinyaku Co.,Ltd. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $897.73
- PY2024
- $22,687.78
What the Data Shows for Nippon Shinyaku Co.,Ltd
Rank #1517 of 1,925 companies in CMS Open Payments for 2024 belongs to Nippon Shinyaku Co.,Ltd, which reported $22,687.78 across 18 transactions to 18 recipients - a comparatively small 0.0% slice of all industry payments reported nationwide for the year. Averages work out to $1.3K per transaction and $1.3K per recipient.
"Travel and Lodging" leads the 4-category general-payment breakdown below at $16.4K (72.3% of General Payments, 9 transactions) - see our methodology for how research and ownership payments are reported separately.
General Payment Breakdown by Type
"Travel and Lodging" leads Nippon Shinyaku Co.,Ltd's 4-category general-payment breakdown at $16.4K, 72.3% of the reported total.
Nippon Shinyaku Co.,Ltd reports 4 general-payment categories - the top three are Travel and Lodging (72.3%), Honoraria (27.0%), and Food and Beverage (0.6%). The remaining 1 category make up 0.1% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Nippon Shinyaku Co.,Ltd divides its payments
General-payment categories, ordered by reported total
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Travel and Lodging | $16.4K | 9 | 72.3% |
| Honoraria | $6.1K | 4 | 27.0% |
| Food and Beverage | $134.65 | 4 | 0.6% |
| Gift | $20.92 | 1 | 0.1% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $22,687.78 (100.0%) of $22,687.78 in this company's General Payments records across 2 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Nippon Shinyaku Co.,Ltd
The five named recipients with the highest reported General Payments from this company
- 1
Courtney D DiNardo
$21,488.05 across 12 reported transactions
- 2
Toshiki Takenouchi
$1,199.73 across 6 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Nippon Shinyaku Co.,Ltd's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Nippon Shinyaku Co.,Ltd.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Nippon Shinyaku Co.,Ltd.
Showing 6 of 1,924 companies with CMS-reported payment data.
Carter Bloodcare
$22.6K 109 recipients
Compare payment profiles
CDC Medical LLC
$22.6K 231 recipients
Compare payment profiles
Innovative Medical Products, Inc.
$22.8K 14 recipients
Compare payment profiles
Reel Surgical, Inc.
$22.5K 214 recipients
Compare payment profiles
NovoSource, LLC
$22.9K 6 recipients
Compare payment profiles
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.